Attach to Form 990 or Form 990-EZ.
Go to
www.irs.gov/Form990 for instructions and the latest information.
| (i) Name of supported organization | (ii) EIN | (iii) Type of organization (described on lines 1- 10 above (see instructions)) | (iv) Is the organization listed in your governing document? | (v) Amount of monetary support (see instructions) | (vi) Amount of other support (see instructions) | |
|---|---|---|---|---|---|---|
| Yes | No | |||||
|
Total |
||||||
Calendar year
(or fiscal year beginning in)
![]() |
(a) 2018 | (b) 2019 | (c) 2020 | (d) 2021 | (e) 2022 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 1 | Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grant.") .. | 215,659,011 | 194,074,339 | 190,647,071 | 203,302,047 | 189,472,784 | 993,155,252 |
| 2 | Tax revenues levied for the organization's benefit and either paid to or expended on its behalf.... | ||||||
| 3 | The value of services or facilities furnished by a governmental unit to the organization without charge.. | ||||||
| 4 | Total. Add lines 1 through 3 | 215,659,011 | 194,074,339 | 190,647,071 | 203,302,047 | 189,472,784 | 993,155,252 |
| 5 | The portion of total contributions by each person (other than a governmental unit or publicly supported organization) included on line 1 that exceeds 2% of the amount shown on line 11, column (f) .. | ||||||
| 6 | Public support. Subtract line 5 from line 4. | 993,155,252 | |||||
Calendar year
(or fiscal year beginning in)
![]() |
(a) 2018 | (b) 2019 | (c) 2020 | (d) 2021 | (e) 2022 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 7 | Amounts from line 4.. | 215,659,011 | 194,074,339 | 190,647,071 | 203,302,047 | 189,472,784 | 993,155,252 |
| 8 | Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources... | 2,438,175 | 2,918,738 | 2,297,884 | 2,679,458 | 8,011,697 | 18,345,952 |
| 9 | Net income from unrelated business activities, whether or not the business is regularly carried on.. | ||||||
| 10 | Other income. Do not include gain or loss from the sale of capital assets (Explain in Part VI.).. | 2,313,482 | 1,671,720 | 3,345,522 | 22,507,054 | 23,469,681 | 53,307,459 |
| 11 | Total support. Add lines 7 through 10 | 1,065,180,308 | |||||
Calendar year (or fiscal year beginning in) ![]() |
(a) 2018 | (b) 2019 | (c) 2020 | (d) 2021 | (e) 2022 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 1 | Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grants.") . | ||||||
| 2 | Gross receipts from admissions, merchandise sold or services performed, or facilities furnished in any activity that is related to the organization's tax-exempt purpose | ||||||
| 3 | Gross receipts from activities that are not an unrelated trade or business under section 513 ..... | ||||||
| 4 | Tax revenues levied for the organization's benefit and either paid to or expended on its behalf... | ||||||
| 5 | The value of services or facilities furnished by a governmental unit to the organization without charge | ||||||
| 6 | Total. Add lines 1 through 5 | ||||||
| 7a | Amounts included on lines 1, 2, and 3 received from disqualified persons | ||||||
| b | Amounts included on lines 2 and 3 received from other than disqualified persons that exceed the greater of $5,000 or 1% of the amount on line 13 for the year. | ||||||
| c | Add lines 7a and 7b.. | ||||||
| 8 | Public support. (Subtract line 7c from line 6.) | ||||||
Calendar year (or fiscal year beginning in) ![]() |
(a) 2018 | (b) 2019 | (c) 2020 | (d) 2021 | (e) 2022 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 9 | Amounts from line 6... | ||||||
| 10a | Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources.. | ||||||
| b | Unrelated business taxable income (less section 511 taxes) from businesses acquired after June 30, 1975. | ||||||
| c | Add lines 10a and 10b. | ||||||
| 11 | Net income from unrelated business activities not included on line 10b, whether or not the business is regularly carried on. | ||||||
| 12 | Other income. Do not include gain or loss from the sale of capital assets (Explain in Part VI.) .. | ||||||
| 13 | Total support. (Add lines 9, 10c, 11, and 12.).. | ||||||
| Section A - Adjusted Net Income | (A) Prior Year |
(B) Current Year (optional) |
||||
| 1 | Net short-term capital gain | 1 | ||||
| 2 | Recoveries of prior-year distributions | 2 | ||||
| 3 | Other gross income (see instructions) | 3 | ||||
| 4 | Add lines 1 through 3 | 4 | ||||
| 5 | Depreciation and depletion | 5 | ||||
| 6 | Portion of operating expenses paid or incurred for production or collection of gross income or for management, conservation, or maintenance of property held for production of income (see instructions) | 6 | ||||
| 7 | Other expenses (see instructions) | 7 | ||||
| 8 | Adjusted Net Income (subtract lines 5, 6 and 7 from line 4) | 8 | ||||
| Section B - Minimum Asset Amount | (A) Prior Year |
(B) Current Year (optional) |
||||
| 1 | Aggregate fair market value of all non-exempt-use assets (see instructions for short tax year or assets held for part of year): | 1 | ||||
| a | Average monthly value of securities | 1a | ||||
| b | Average monthly cash balances | 1b | ||||
| c | Fair market value of other non-exempt-use assets | 1c | ||||
| d | Total (add lines 1a, 1b, and 1c) | 1d | ||||
| e |
Discount claimed for blockage or other factors (explain in detail in Part VI): |
|||||
| 2 | Acquisition indebtedness applicable to non-exempt use assets | 2 | ||||
| 3 | Subtract line 2 from line 1d | 3 | ||||
| 4 | Cash deemed held for exempt use. Enter 0.015 of line 3 (for greater amount, see instructions). | 4 | ||||
| 5 | Net value of non-exempt-use assets (subtract line 4 from line 3) | 5 | ||||
| 6 | Multiply line 5 by 0.035 | 6 | ||||
| 7 | Recoveries of prior-year distributions | 7 | ||||
| 8 | Minimum Asset Amount (add line 7 to line 6) | 8 | ||||
| Section C - Distributable Amount | Current Year | |||||
| 1 | Adjusted net income for prior year (from Section A, line 8, Column A) | 1 | ||||
| 2 | Enter 85% of line 1 | 2 | ||||
| 3 | Minimum asset amount for prior year (from Section B, line 8, Column A) | 3 | ||||
| 4 | Enter greater of line 2 or line 3 | 4 | ||||
| 5 | Income tax imposed in prior year | 5 | ||||
| 6 | Distributable Amount. Subtract line 5 from line 4, unless subject to emergency temporary reduction (see instructions) | 6 | ||||
| Section D - Distributions | Current Year | |
|---|---|---|
| 1 Amounts paid to supported organizations to accomplish exempt purposes | 1 | |
|
2
Amounts paid to perform activity that directly furthers exempt purposes of supported organizations, in excess of income from activity |
2 | |
| 3 Administrative expenses paid to accomplish exempt purposes of supported organizations | 3 | |
| 4 Amounts paid to acquire exempt-use assets | 4 | |
| 5 Qualified set-aside amounts (prior IRS approval required - provide details in Part VI) | 5 | |
| 6 Other distributions (describe in Part VI). See instructions | 6 | |
| 7Total annual distributions. Add lines 1 through 6. | 7 | |
|
8
Distributions to attentive supported organizations to which the organization is responsive (provide details in Part VI). See instructions |
8 | |
| 9 Distributable amount for 2022 from Section C, line 6 | 9 | |
| 10 Line 8 amount divided by Line 9 amount | 10 | |
| Section E - Distribution Allocations (see instructions) |
(i) Excess Distributions |
(ii) Underdistributions Pre-2022 |
(iii) Distributable Amount for 2022 |
|
|---|---|---|---|---|
| 1 Distributable amount for 2022 from Section C, line 6 | ||||
|
2
Underdistributions, if any, for years prior to 2022 (reasonable cause required-- explain in Part VI).
See instructions. |
||||
| 3 Excess distributions carryover, if any, to 2022: | ||||
| a From 2017....... | ||||
| b From 2018....... | ||||
| c From 2019....... | ||||
| d From 2020....... | ||||
| e From 2021....... | ||||
| fTotal of lines 3a through e | ||||
| g Applied to underdistributions of prior years | ||||
| h Applied to 2022 distributable amount | ||||
|
i
Carryover from 2017 not applied (see instructions) |
||||
| j Remainder. Subtract lines 3g, 3h, and 3i from line 3f. | ||||
| 4Distributions for 2022 from Section D, line 7: | ||||
| $ | ||||
| a Applied to underdistributions of prior years | ||||
| b Applied to 2022 distributable amount | ||||
| c Remainder. Subtract lines 4a and 4b from line 4. | ||||
|
5
Remaining underdistributions for years prior to 2022, if any. Subtract lines 3g and 4a from line 2. If the amount is greater than zero, explain in Part VI. See instructions. |
||||
|
6
Remaining underdistributions for 2022. Subtract lines 3h and 4b from line 1. If the amount is greater than zero, explain in Part VI. See instructions. |
||||
|
7 Excess distributions carryover to 2023. Add lines 3j and 4c. |
||||
| 8 Breakdown of line 7: | ||||
| a Excess from 2018..... | ||||
| b Excess from 2019..... | ||||
| c Excess from 2020..... | ||||
| d Excess from 2021..... | ||||
| e Excess from 2022..... | ||||
| Facts And Circumstances Test |
|---|
| Return Reference | Explanation |
|---|---|
| SCHEDULE A, PART II, LINE 10, EXPLANATION OF OTHER INCOME: | PROGRAM RELATED INVESTMENT OTHER EXCLUDED INCOME - 2018 AMOUNT: $ 2,313,482. 2019 AMOUNT: $ 1,671,720. 2020 AMOUNT: $ 3,345,522. 2021 AMOUNT: $ 22,507,054. 2022 AMOUNT: $ 23,469,681. |
| Software ID: | |
| Software Version: |
Attach to Form 990 or 990-EZ.
Go to www.irs.gov/Form990 for the latest information.
| Return Reference | Explanation |
|---|---|
| FORM 990, PART I, LINE 1 AND PART III, LINE 1 - ORGANIZATION'S MISSION | AT JDRF, WE WORK TIRELESSLY TO ACCELERATE BREAKTHROUGHS TO CURE, PREVENT AND TREAT TYPE 1 DIABETES (T1D). WE CONTINUALLY EXPAND OUR SCIENTIFIC KNOWLEDGE, OUR CONNECTIONS AND COLLABORATIONS, OUR PARTNERS AND GLOBAL PRESENCE TO UNLOCK THE SCIENCE THAT WILL STOP T1D. WHILE WE FIGHT FOR A CURE, WE STRIVE JUST AS HARD TO DEVELOP THERAPIES TO HELP PEOPLE RIGHT NOW. JDRF AND OUR SCIENTISTS ARE LEADING T1D RESEARCH AROUND THE WORLD. WE ADDRESS KEY GAPS TO MOVE RESEARCH FASTER AND FARTHER ACROSS THE DEVELOPMENT PIPELINE AND TO TRANSLATE BREAKTHROUGHS INTO NEW THERAPIES FOR PEOPLE WITH T1D. THIS ENABLES US TO ADVANCE SCIENCE WITH THE MOST POTENTIAL AND TO DRIVE RESEARCH THAT ATTRACTS MORE RESOURCES AND SCIENTIFIC EXPERTISE TO THE FIELD. WE INVEST IN THE EARLY STAGES, ALLOWING RESEARCHERS TO PURSUE INNOVATIVE IDEAS AND APPROACHES THAT WILL LEAD TO BREAKTHROUGH TREATMENTS. JDRF ALSO WORKS TO DRIVE NEW THERAPIES AND TECHNOLOGIES TO MARKET SO THEY GET INTO THE HANDS OF PEOPLE WITH T1D MORE QUICKLY. AND WE CONNECT THE T1D COMMUNITY TO CREATE A GLOBAL COMMUNITY OF SUPPORT FOR ANYONE AFFECTED BY T1D. FROM FUNDING INNOVATIVE RESEARCH TO ADVOCATING FOR GOVERNMENT ACTION AND PROVIDING A SUPPORT STRUCTURE FOR OUR COMMUNITY, NO OTHER ORGANIZATION DOES MORE TO FIGHT T1D THAN JDRF. SINCE OUR FOUNDING, JDRF HAS FUNDED MORE THAN $2.5 BILLION IN RESEARCH AND HAS MADE SIGNIFICANT PROGRESS IN UNDERSTANDING AND FIGHTING THE DISEASE. OUR ACTIONS - THROUGH ADVOCACY AND OUR OWN INVESTMENTS IN T1D RESEARCH - INFLUENCE OTHER ORGANIZATIONS, CORPORATIONS AND GOVERNMENT AGENCIES TO FOLLOW OUR LEAD AND DIRECT ADDITIONAL FUNDING TOWARD T1D RESEARCH. TODAY, EVERY $1 JDRF INVESTS IN RESEARCH ATTRACTS AN ADDITIONAL $2.25 TO THE FIELD. FOR FISCAL YEAR 2023, JDRF'S APPROXIMATELY $138.4 MILLION IN DIRECT FUNDING ATTRACTED $311 MILLION IN ADDITIONAL INVESTMENT IN T1D RESEARCH FROM U.S. AND INTERNATIONAL GOVERNMENT, NGOS AND CHARITABLE ORGANIZATIONS, AND CORPORATE PARTNERS. |
| FORM 990, PART III, LINE 4A: RESEARCH GRANTS | JDRF HAS PLAYED A SIGNIFICANT ROLE IN NEARLY EVERY T1D ADVANCE--DRUG, DEVICE, CELL THERAPY--MADE IN THE LAST 50 YEARS. OUR FUNDING SUPPORTS MORE THAN 400 ACTIVE T1D RESEARCH GRANTS IN THE UNITED STATES AND 20+ OTHER COUNTRIES AROUND THE WORLD, INCLUDING 159 GRANTS IN FY2023 ALONE, PLUS 78 CLINICAL TRIALS. WE LEVERAGE PARTNERSHIPS WITH ACADEMIA, INDUSTRY, AND CLINICIANS TO ACCELERATE THE MOST PROMISING RESEARCH OPPORTUNITIES. OUR HIGHEST PRIORITY IS DEVELOPING CURES FOR T1D AND IMPROVING LIVES OF THOSE LIVING WITH THE DISEASE TODAY, INCLUDING RESEARCH IN GLUCOSE CONTROL AND PREVENTION OF T1D COMPLICATIONS. THE FULL IMPACT OF JDRF'S RESEARCH INVESTMENT EXTENDS WELL BEYOND DIRECT FUNDING. THROUGH ADVOCACY AND INFLUENCE, JDRF DRIVES FUNDING FROM OTHER SOURCES INTO T1D RESEARCH AND HAS HELPED SECURE PASSAGE OF THE SPECIAL DIABETES PROGRAM, PUTTING NEARLY $3.5 BILLION IN FEDERAL FUNDING TOWARD T1D RESEARCH OVER THE LAST TWO DECADES. ADDITIONALLY, JDRF FOUNDED THE JDRF T1D FUND (T1DFUND.ORG), WHICH IS A WHOLLY OWNED ENTITY OF JDRF. THE T1D FUND IS A VENTURE PHILANTHROPY FUND ACCELERATING LIFE-CHANGING SOLUTIONS TO TREAT, PREVENT, AND CURE T1D THROUGH CATALYTIC COMMERCIAL INVESTMENTS. THROUGH ITS INVESTMENTS IN PARTNERSHIP WITH PRIVATE CAPITAL, INCLUDING VENTURE CAPITAL, PHARMA, AND FOUNDATIONS, THE T1D FUND SEEKS TO ATTRACT THE PRIVATE INVESTMENT NECESSARY TO ADVANCE DRUGS, DEVICES, DIAGNOSTICS, AND VACCINES TO HELP PEOPLE LIVING WITH T1D AND THOSE WHO ARE AT RISK OF DEVELOPING THE DISEASE. THE T1D FUND INVESTS IN OPPORTUNITIES THAT DRIVE OUR MISSION, WITH AN EXCLUSIVE FOCUS ON THE MOST PROMISING COMMERCIAL OPPORTUNITIES. ALL FUNDS GO DIRECTLY TO SUPPORT COMPANIES DEVELOPING APPROACHES TO TREAT, PREVENT, AND CURE T1D. IN ACCORDANCE WITH GAAP, THE T1D FUND'S TOTAL INVESTMENTS AS OF JUNE 30, 2023, TOTALING $70.1 MILLION, ARE REFLECTED IN THE BALANCE SHEET (PART X) AND NOT INCLUDED WITHIN JDRF'S RESEARCH-RELATED MISSION EXPENSE. JDRF'S DIVERSIFIED RESEARCH PORTFOLIO INCLUDES A FOCUS ON CURING T1D AND IMPROVING LIVES. CURING T1D WE FACE TWO KEY CHALLENGES IN CURING T1D. WE MUST PREVENT, STOP, OR REVERSE THE (1) LOSS OF INSULIN-PRODUCING BETA CELLS AND (2) THE IMMUNE SYSTEM'S ATTACK ON BETA CELLS. JDRF IS ACCELERATING OUR WORK IN CURING T1D BY FOCUSING ON THREE AREAS THAT HAVE ADVANCED DRAMATICALLY OVER THE YEARS: SCREENING FOR RISK OF T1D, CELL THERAPIES, AND DISEASE-MODIFYING THERAPIES. SCREENING FOR RISK OF T1D: FOCUS ON EXPANDING SCREENING FOR T1D-RELATED AUTOANTIBODIES AND SCREENING AWARENESS. DONOR-FUNDED RESEARCH HAS DISCOVERED THAT HAVING TWO OR MORE T1D-SPECIFIC ANTIBODIES MEANS THAT YOU HAVE AN ALMOST 100% CHANCE OF DEVELOPING DIABETES IN YOUR LIFETIME. WITH ONE BLOOD TEST, YOU CAN FIND OUT-BEFORE SYMPTOMS APPEAR-IF YOU ARE AT RISK. THIS CAN REDUCE THE RISK OF DIABETIC KETOACIDOSIS AND HOSPITALIZATION AT THE ONSET OF SYMPTOMS AND IDENTIFY PEOPLE WHO CAN TAKE PART IN CLINICAL TRIALS TO DELAY OR PREVENT T1D. CELL THERAPIES: FOCUS ON REPLACING INSULIN-PRODUCING BETA CELLS FROM OUTSIDE SOURCES SUCH AS STEM CELLS OR NON-HUMAN CELLS. THROUGH DONOR-FUNDED RESEARCH, WE NOW KNOW THAT WHEN SOMEONE HAS T1D, THEIR OWN BODY BEGINS ATTACKING AND DESTROYING THE BETA CELLS THAT CREATE INSULIN. IF WE CAN REPLACE BETA CELLS, WE CAN HELP FIND CURES FOR T1D. THERE IS EARLY BUT CRUCIAL PROGRESS SEEN IN RECENTLY REPORTED CLINICAL TRIALS WHERE BETA CELL REPLACEMENT HAS MADE ADVANCES TOWARD INSULIN INDEPENDENCE, BETTER T1D CONTROL, AND LONGEVITY OF THE THERAPIES. DISEASE-MODIFYING THERAPIES: RESEARCH HAS SHOWN THAT A PERSON'S IMMUNE SYSTEM MISTAKENLY DESTROYS THE BODY'S BETA CELLS, RENDERING THE PERSON INSULIN-DEPENDENT FOR LIFE. IF WE CAN FIND WAYS TO KEEP THE IMMUNE SYSTEM FROM ATTACKING AND DESTROYING BETA CELLS, PROVIDE WAYS TO PROTECT AND TO SPUR THEM, AND DEVELOP TREATMENTS THAT CAN SLOW, HALT, OR REVERSE T1D, AT ANY AGE OR STAGE OF THE DISEASE, WE WILL BE ON THE PATHWAY TO PREVENTION AND CURES FOR T1D. IMPROVING LIVES T1D BRINGS WITH IT DAILY STRUGGLES AND STRESSES THAT THAT MAKE THE CHALLENGES OF LIVING A HEALTHY AND LONG LIFE WITH T1D VERY REAL. JDRF FIGHTS EVERY DAY TO ADVANCE RESEARCH THAT CAN REDUCE THE BURDEN OF LIVING WITH T1D AND KEEP PEOPLE AS HEALTHY AS POSSIBLE UNTIL WE FIND CURES. SPECIFICALLY, WE ARE STRIVING TO IMPROVE LIVES BY ACCELERATING THE DEVELOPMENT OF DRUGS, DEVICES, BEHAVIORAL HEALTH INTERVENTIONS, AND COMBINATIONS OF THESE, TO IMPROVE SHORT- AND LONG-TERM HEALTH OUTCOMES AND QUALITY OF LIFE, THROUGH THE FOLLOWING THREE PROGRAMS. GLUCOSE CONTROL: WE KNOW THAT FEWER THAN 30% OF PEOPLE WITH T1D IN THE U.S. CONSISTENTLY MAINTAIN TARGET BLOOD-GLUCOSE LEVELS-MEANING THAT 70% ARE AT RISK OF SERIOUS HEALTH ISSUES. AIMING TO ENSURE OUR COMMUNITY IS HEALTHY WHEN CURES ARE FOUND, WE WILL CONTINUE TO FOCUS ON HELPING THOSE WITH T1D MANAGE GLUCOSE LEVELS AND OVERALL METABOLIC BALANCE, INCLUDING IMPROVED ARTIFICIAL PANCREAS TECHNOLOGY, DEVELOPING NEXT-GENERATION INSULINS, AND DEVELOPING NEW DRUGS THAT CONTROL GLUCOSE AND OTHER METABOLIC FACTORS IN NOVEL WAYS. COMPLICATIONS: FOCUS ON ACCELERATING THERAPIES THAT PREVENT AND TREAT EYE, KIDNEY, AND HEART DISEASE. MORE THAN 90% OF PEOPLE WITH T1D DEVELOP SOME LEVEL OF EYE DISEASE WITHIN 20 YEARS OF DIAGNOSIS, 1 IN 4 DEVELOP KIDNEY DISEASE, AND HEART ATTACKS AND STROKES CAUSE APPROXIMATELY 3 OUT OF EVERY 4 DEATHS IN PEOPLE WITH T1D. JDRF DIRECTS FUNDS TO DEVELOP AND IMPROVE EYE, KIDNEY, AND HEART DISEASE TREATMENTS, SO THAT PEOPLE AT RISK CAN TAKE STEPS TO INTERVENE EARLY IN THE DISEASE PROCESS. PSYCHOSOCIAL HEALTH: FOCUS ON REDUCING THE PSYCHOSOCIAL CHALLENGES OF T1D. EARLY RESEARCH HAS SHOWN THAT THE BURDEN OF LIVING WITH T1D TAKES A TOLL BEYOND THE PHYSICAL COMPLICATIONS, OFTEN AFFECTING PEOPLE'S SOCIAL, BEHAVIORAL, AND EMOTIONAL WELL-BEING, KNOWN COLLECTIVELY AS PSYCHOSOCIAL HEALTH. WE AIM TO REDUCE THE CHALLENGES THROUGH INCREASING THE NUMBER OF AND PROVIDING ACCESS TO PSYCHOLOGISTS TRAINED IN T1D, SUPPORTING RESEARCH INITIATIVES TO IMPROVE PSYCHOSOCIAL HEALTH AND OUTCOMES, AND EDUCATING THE T1D COMMUNITY ABOUT THE PSYCHOSOCIAL IMPACT OF THE DISEASE. |
| FORM 990, PART III, LINE 4B: PUBLIC EDUCATION | JDRF IS UNIQUELY QUALIFIED TO PROVIDE PUBLIC EDUCATION ABOUT TYPE 1 DIABETES AND ITS COMPLICATIONS. JDRF'S EFFORTS IMPACT NOT ONLY THE MILLIONS OF PEOPLE LIVING WITH T1D, THEIR FAMILIES, AND THE GENERAL PUBLIC, BUT ALSO THOSE AT RISK FOR DEVELOPING THE DISEASE. T1D STRIKES BOTH CHILDREN AND ADULTS, AND THE CRITICAL ADJUSTMENT PERIOD FOLLOWING A DIAGNOSIS CAN BE OVERWHELMING. THAT'S WHY WE SUPPORT FAMILIES NAVIGATING THIS CHALLENGING TIME. JDRF ALSO EDUCATES PEOPLE ABOUT THE WARNING SIGNS OF T1D, AIMED AT ENSURING TIMELY DIAGNOSES AND REDUCING THE POTENTIAL CATASTROPHIC CONSEQUENCES OF UNDIAGNOSED T1D. JDRF ALSO PROVIDES INFORMATION AND UPDATES ABOUT CURRENT RESEARCH DIRECTIONS AND PROGRESS AND ABOUT HUMAN CLINICAL TRIALS THAT ARE SEEKING PARTICIPANTS (INCLUDING THROUGH JDRF'S CLINICAL TRIALS CONNECTION MATCHING TOOL: JDRF.ORG/CLINICAL-TRIALS). THROUGH ALL OF OUR NATIONAL U.S. CHAPTERS; FIVE INTERNATIONAL AFFILIATES IN AUSTRALIA, CANADA, ISRAEL, THE NETHERLANDS, AND UNITED KINGDOM; THE 30,000 MEMBERS OF OUR SOCIAL NETWORK, TYPEONENATION; AND MORE THAN ONE MILLION SUPPORTERS, JDRF FIGHTS TO MEET THE T1D COMMUNITY'S DIVERSE NEEDS, CONNECTING PEOPLE WITH LOCAL SUPPORT, EXPERT RESOURCES, AND THE GLOBAL EFFORT TO CREATE A WORLD WITHOUT T1D. |
| FORM 990, PART III, LINE 4C: RESEARCH SUPPORT | JDRF'S IN-HOUSE TEAM OF SKILLED AND CREDENTIALED SCIENTIFIC, POLICY, AND GOVERNMENT RELATIONS PROFESSIONALS PLAYS A CRITICAL ROLE IN LEADING AND SUPPORTING THE RESEARCH STRATEGY AND DISTRIBUTION OF RESEARCH FUNDS FROM JDRF-AND OUR PARTNER ORGANIZATIONS-TOWARD CREATING A WORLD WITHOUT T1D. OUR PROFESSIONALS IDENTIFY, EVALUATE, AND INFLUENCE GROUNDBREAKING RESEARCH FOR FUNDING AND WORK WITH OTHER FOUNDATIONS, GOVERNMENTS, AND INDUSTRY PARTNERS TO ACCELERATE THE MISSION WE ALL SHARE. JDRF PROFESSIONALS WORK WITH REGULATORY AND POLICY OFFICIALS TO ENSURE RESEARCH CAN PROCEED WITHOUT DELAY AND THAT ADVANCES ARE WELL UNDERSTOOD BY HEALTHCARE DECISION MAKERS. AS PART OF THESE EFFORTS, JDRF ORGANIZES AND FUNDS SCIENTIFIC MEETINGS, SYMPOSIA, AND CONFERENCES TO ENSURE THAT JDRF'S RESEARCH STRATEGY IS ALIGNED WITH THE NEEDS OF THE T1D COMMUNITY AND ALLOW JDRF TO PROVIDE SCIENTIFIC UPDATES ON THE RESEARCH IT MANAGES. THIS EFFORT ENSURES THAT ALL THE RESEARCH IS CONTINUALLY SHARED AND BUILT UPON BY T1D RESEARCHERS AROUND THE GLOBE. THE STRATEGIC ADVISORY PANEL (SAP) IS COMPOSED OF FIVE ESTABLISHED T1D EXPERTS IN VARIOUS ASPECTS OF THE FIELD, INCLUDING PEDIATRIC ENDOCRINOLOGY, PREVENTION, AND TREATMENT OF T1D, IMMUNOTHERAPIES, REGULATORY, AND DRUG DEVELOPMENT. THE SAP CONTRIBUTES TO JDRF SCIENTISTS' STRATEGIC PLANNING AROUND RESEARCH FUNDING GOALS AND PRIORITIES. JDRF'S WORK TO BRING TOGETHER THE BEST MINDS IN THE FIELD ENHANCES JDRF'S ABILITY TO FORECAST FUTURE SCIENTIFIC DIRECTION, JUDGE THE POTENTIAL EFFECTIVENESS OF NEW PATHWAYS, AND IDENTIFY GAPS WHERE JDRF FUNDING CAN MAKE THE MOST IMPACT. |
| FORM 990, PART VI, SECTION B, LINE 11B | FORM 990 REVIEW PROCESS JDRF HAS A RIGOROUS STANDARD APPROACH TO REVIEWING ITS 990. THE ORGANIZATION'S ACCOUNTING MANAGER WORKS WITH ITS OUTSIDE TAX PREPARERS TO PREPARE THE RETURN AND ALL SUPPORTING SCHEDULES. THE DRAFT RETURN IS REVIEWED BY A NUMBER OF INDIVIDUALS, INCLUDING JDRF'S CHIEF FINANCIAL OFFICER, OTHER EXECUTIVES, ITS EXTERNAL SENIOR TAX ADVISOR AND OTHERS AS NECESSARY TO ENSURE ACCURACY. ANY QUESTIONS AND CHANGES WITH RESPECT TO THE DRAFT RETURNS ARE ADDRESSED. FOLLOWING THIS PROCESS, THE RETURN IS REVIEWED BY JDRF'S AUDIT AND RISK COMMITTEE OF THE BOARD OF DIRECTORS WITH ITS OUTSIDE TAX ADVISORS. ONCE APPROVED, THE RETURN IS DISTRIBUTED TO ALL MEMBERS OF JDRF'S BOARD OF DIRECTORS FOR REVIEW AND COMMENT BEFORE IT IS FILED WITH THE INTERNAL REVENUE SERVICE. |
| FORM 990, PART VI, SECTION B, LINE 12C | CONFLICT OF INTEREST POLICY COVERED PERSONS COMPLETE A CONFLICT OF INTEREST DISCLOSURE FORM AND ACKNOWLEDGE THE JDRF CODE OF ETHICS AT THE BEGINNING OF EACH FISCAL YEAR. COVERED PERSONS INCLUDE: MEMBERS OF THE INTERNATIONAL BOARD OF DIRECTORS, DIRECTORS EMERITUS, MEMBERS OF THE GLOBAL MISSION BOARD, CHAPTER DIRECTORS AND OFFICERS, DIRECTORS OF THE JDRF T1D FUND, AND MEMBERS OF THE T1D FUND INVESTMENT COMMITTEE. WHEN A CONFLICT IS DISCLOSED, THE COVERED PERSON SHALL ABSTAIN FROM PARTICIPATING IN DECISIONS AND/OR DISCUSSIONS INVOLVING JDRF'S BUSINESS OR RELATIONSHIP WITH THE RELEVANT THIRD PARTY. IF THE COVERED PERSON IS ASKED TO ABSTAIN, THE COVERED PERSON MAY STILL BE PERMITTED TO STATE HIS OR HER POSITION ON SUCH MATTER AND TO ANSWER PERTINENT QUESTIONS AND INQUIRIES RELATING THERETO. THE COVERED PERSON MAY BE ASKED TO LEAVE THE MEETING DURING THE DISCUSSION OF AND/OR VOTE ON THE MATTER INVOLVING THE RELEVANT THIRD PARTY. |
| FORM 990, PART VI, SECTION B, LINE 15 | EXECUTIVE COMPENSATION POLICY JDRF'S BOARD OF DIRECTORS CHARGES A TALENT AND COMPENSATION COMMITTEE TO DEVELOP AND RECOMMEND A COMPENSATION PHILOSOPHY THAT APPLIES TO ALL EMPLOYEES OF THE FOUNDATION, INCLUDING RECOMMENDATIONS REGARDING THE COMPENSATION AND BENEFITS OF FOUNDATION SENIOR MANAGEMENT FOR APPROVAL BY THE BOARD OF DIRECTORS. THE COMMITTEE WORKS IN COLLABORATION WITH THE CEO AND THE CHIEF HUMAN RESOURCES OFFICER AND OTHER SENIOR STAFF PERSONNEL IN THE JDRF HUMAN RESOURCES DEPARTMENT TO ENSURE THAT 1) THE FOUNDATION'S TALENT STRATEGY SUPPORTS AND IS ALIGNED WITH ITS OVERALL ORGANIZATION STRATEGIES; 2) JDRF IS IN COMPLIANCE WITH IRS GUIDELINES FOR DETERMINING REASONABLENESS IN PAY PRACTICES; AND 3) OVERALL COMPENSATION FOR THE FOUNDATION'S KEY EXECUTIVES IS COMPETITIVE AND ALIGNED WITH PAY PHILOSOPHY. TO ATTRACT AND RETAIN TOP SCIENTIFIC AND EXECUTIVE TALENT TO ADVANCE ITS MISSION, THE FOUNDATION PAYS COMPETITIVE AND APPROPRIATE SALARIES AS DETERMINED BY ANALYSIS OF RELIABLE DATA AND INPUT FROM INDEPENDENT THIRD-PARTY CONSULTANTS. THE REVIEW OF FOUNDATION EXECUTIVE COMPENSATION AND BENEFITS UNDER THE PROCEDURES NOTED ABOVE IS COMPLETED ANNUALLY BY AN INDEPENDENT COMPENSATION COMMITTEE, AND THE BASIS FOR THEIR DETERMINATION IS DOCUMENTED CONTEMPORANEOUSLY IN THE MINUTES OF THE COMMITTEE'S MEETINGS, INCLUDING MOST RECENTLY ON JUNE 30, 2023. SIMILARLY, A SEPARATE TALENT AND COMPENSATION COMMITTEE OF THE T1D FUND IS CHARGED WITH ENSURING THAT 1) THE FUND'S TALENT STRATEGY SUPPORTS AND IS ALIGNED WITH ITS OVERALL ORGANIZATION STRATEGIES; 2) JDRF IS IN COMPLIANCE WITH IRS GUIDELINES FOR DETERMINING REASONABLENESS IN PAY PRACTICES; AND 3) OVERALL COMPENSATION FOR THE FUND'S KEY EXECUTIVES IS COMPETITIVE AND ALIGNED WITH PAY PHILOSOPHY. |
| FORM 990, PART VI, SECTION C, LINE 19 | PUBLIC DOCUMENTS THE ORGANIZATION MAKES ITS GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY AND FINANCIAL STATEMENTS AVAILABLE TO THE PUBLIC ON ITS WEBSITE: WWW.JDRF.ORG. THE PUBLIC MAY ACCESS COPIES OF JDRF'S W-9, ANNUAL REPORTS, 990 TAX RETURNS, 501(C)(3) IRS LETTER, AND AUDITED FINANCIALS, AT THE FOLLOWING LINK: WWW.JDRF.ORG/ABOUT/FINANCIALS. |
| Software ID: | |
| Software Version: |